High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1Jennifer L. Schehr, Joshua M. Lang, Anne M. Traynor et al.|PLoS ONE|2016Cited by 63
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancerShuang G. Zhao, Joshua M. Lang, Jamie M. Sperger et al.|Journal of Clinical Investigation|2022Cited by 33
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell CarcinomaMatthew L. Bootsma, Shuang G. Zhao, Rana R. McKay et al.|Journal of Clinical Oncology|2022Cited by 28
Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extractionHannah M. Pezzi, David J. Beebe, David J. Guckenberger et al.|Lab on a Chip|2018Cited by 25
Abstract 2246: Androgen receptor expression in non-small cell lung cancer circulating tumor cellsJennifer L. Schehr, Joshua M. Lang, Zachery D. Schultz et al.|Cancer Research|2016Cited by 0